Lifetech Scientific Corporation (HKG: 1302) announced that its self‑developed IBS Absorbable Drug‑Eluting Coronary Stent System has received CE MDR certification from the European Union, making it the world’s first iron‑based absorbable coronary stent system to obtain market approval – a landmark for the next generation of coronary intervention devices.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Lifetech Scientific Corporation (HKG: 1302) |
| Product | IBS Absorbable Drug‑Eluting Coronary Stent System |
| Regulatory Body | European Union (Notified Body assessment under MDR) |
| Certification Type | CE MDR certification |
| Announcement Date | 2 November 2026 |
| Distinction | World’s first iron‑based absorbable coronary stent to obtain market approval |
| EU Commercial Launch Timeline | Not disclosed |
Device Profile & Technology
- Platform: The IBS coronary stent is the world’s first fully degradable, iron‑based absorbable coronary stent, independently developed by Lifetech Scientific.
- Backbone Material: Fabricated from high‑purity nitrided iron tubing featuring high strength and high plasticity – the material foundation enabling iron‑based bioresorption.
- Strut Design: Achieves a thin strut wall of 55–65 μm alongside strong radial support, addressing the historical limitation of bioresorbable scaffolds requiring thick struts.
- Best‑of‑Both‑Worlds Profile: Through innovative materials research and a unique technological approach, the stent retains the advantages of permanent metallic coronary stents – complete size specifications, superior physical properties, excellent biocompatibility, and ease of operation – while adding full absorbability.
- Clinical Rationale: Full resorption after vessel healing effectively mitigates long‑term prognosis issues associated with permanent metallic stent implantation, such as the permanent cage effect on vasomotion and long‑term foreign‑body presence.
Market Impact & Outlook
- Bioresorbable Stent Comeback: Following the well‑documented setbacks of first‑generation polymer bioresorbable scaffolds, the IBS stent’s thin‑strut iron platform offers a credible second attempt at the “vascular restoration” promise – now with EU market authorization in hand.
- First‑Mover Advantage: As the world’s first approved iron‑based absorbable coronary stent, Lifetech Scientific secures a differentiated position in the global coronary intervention market, competing against both permanent drug‑eluting stents and rival bioresorbable programs.
- European Commercialization: CE MDR certification opens the EU market for commercial launch; pricing, distribution partnerships, and rollout timelines were not disclosed.
- Next Catalysts: EU launch execution, real‑world clinical adoption data, and potential expansion of the IBS platform into additional vascular indications within Lifetech’s absorbable device franchise.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of the IBS Absorbable Drug‑Eluting Coronary Stent System in the European Union, market adoption, and future platform expansion. Actual results may differ materially due to launch execution, clinical outcome experience, reimbursement and pricing dynamics, competitive developments, and regulatory requirements in other jurisdictions. EU commercialization timelines and financial terms were not disclosed.-Fineline Info & Tech
